Augmentation strategies in partial responder and/or treatment-resistant schizophrenia patients treated with clozapine

Bibliography

• Hasan A, Falkai P, Wobrock T, et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. World J Biol Psychiatry 2012;13:318-78
   PubMed Web of Science ®Google Scholar
• Kane J, Honingfeld G, Singer J, Meltzer H. Clozapine for the treatment resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988;45:789-96
   PubMed Web of Science ®Google Scholar
• Overall JE, Gorham DR. The brief psychiatric rating scale. Psychol Rep 1962;10:799-812
   Web of Science ®Google Scholar
• Tsang HW, Leung AY, Chung RC, et al. Review on vocational predictors: a systematic review of predictors of vocational outcomes among individuals with schizophrenia: an update since 1998. Aust N Z J Psychiatry 2010;44:495-504
   PubMed Web of Science ®Google Scholar
• Suzuki T, Remington G, Mulsant BH, et al. Treatment resistant schizophrenia and response to antipsychotics: a review. Schizophr Res 2011;133:54-62
   PubMed Web of Science ®Google Scholar
• Bell MD, Corbera S, Johannesen JK, et al. Social cognitive impairments and negative symptoms in schizophrenia: are there subtypes with distinct functional correlates? Schizophr Bull 2013;39:186-96
   PubMed Web of Science ®Google Scholar
• Leucht S, Cipriani A, Spineli L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 2013;382:951-62
   PubMed Web of Science ®Google Scholar
• Lieberman JA, Safferman AZ, Pollack S, et al. Clinical effects of clozapine in chronic schizophrenia: response to treatment and predictors of outcome. Am J Psychiatry 1994;151:1744-52
   PubMed Web of Science ®Google Scholar
• Meltzer HY, Alphs L, Green AI, et al. Clozapine treatment for suicidality in schizophrenia: international Suicide Prevention Trial (InterSePT). Arch Gen Psychiatry 2003;60:82-91
   PubMed Web of Science ®Google Scholar
• Volavka J, Czobor P, Nolan K, et al. Overt aggression and psychotic symptoms in patients with schizophrenia treated with clozapine, olanzapine, risperidone, or haloperidol. J Clin Psychopharmacol 2004;24:225-8
   PubMed Web of Science ®Google Scholar
• Chakos M, Lieberman J, Hoffman E, et al. Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials. Am J Psychiatry 2001;158:518-26
   PubMed Web of Science ®Google Scholar
• Dold M, Leucht S. Pharmacotherapy of treatment-resistant schizophrenia: a clinical perspective. Evid Based Ment Health 2014;17:33-7
   PubMedGoogle Scholar
• Ulrich S, Baumann B, Wolf R, et al. Therapeutic drug monitoring of clozapine and relapse – a retrospective study of routine clinical data. Int J Clin Pharmacol Ther 2003;41:3-13
   PubMed Web of Science ®Google Scholar
• Conley RR, Carpenter WT Jr, Tamminga CA. Time to clozapine response in a standardized trial. Am J Psychiatry 1997;154:1243-7
   PubMedGoogle Scholar
• Sherwood M, Thornton AE, Honer WG. A quantitative review of the profile and time course of symptom change in schizophrenia treated with clozapine. J Psychopharmacol 2012;26:1175-84
   Google Scholar
• Nielsen J, Damkier P, Lublin H, Taylor D. Optimizing clozapine treatment. Acta Psychiatr Scand 2011;123:411-22
   PubMed Web of Science ®Google Scholar
• Cipriani A, Boso M, Barbui C. Clozapine combined with different antipsychotic drugs for treatment resistant schizophrenia. Cochrane Database Syst Rev 2009(3):CD006324
   Google Scholar
• Buchanan RW, Kreyenbuhl J, Kelly DL, et al. The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr Bull 2010;36:71-93
   PubMed Web of Science ®Google Scholar
• Sommer IE, Begemann MJ, Temmerman A, Leucht S. Pharmacological augmentation strategies for schizophrenia patients with insufficient response to clozapine: a quantitative literature review. Schizophr Bull 2012;38:1003-11
   PubMed Web of Science ®Google Scholar
• McEvoy JP, Lieberman JA, Stroup TS, et al. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry 2006;163:600-10
   PubMed Web of Science ®Google Scholar
• Chong SA, Remington G. Clozapine augmentation: safety and efficacy. Schizophr Bull 2000;26:421-40
   PubMed Web of Science ®Google Scholar
• Remington G, Saha A, Chong SA, Shammi C. Augmentation strategies in clozapine-resistant schizophrenia. CNS Drugs 2005;19:843-72
   PubMed Web of Science ®Google Scholar
• Mouaffak F, Tranulis C, Gourevitch R, et al. Augmentation strategies of clozapine with antipsychotics in the treatment of ultraresistant schizophrenia. Clin Neuropharmacol 2006;29:28-33
   PubMed Web of Science ®Google Scholar
• Van Sant SP, Buckley PF. Pharmacotherapy for treatment-refractory schizophrenia. Expert Opin Pharmacother 2011;12:411-34
   PubMed Web of Science ®Google Scholar
• Porcelli S, Balzarro B, Serretti A. Clozapine resistance: augmentation strategies. Eur Neuropsychopharmacol 2012;22:165-82
   PubMed Web of Science ®Google Scholar
• Anil Yağcioğlu AE, Kivircik Akdede BB, Turgut TI, et al. A double-blind controlled study of adjunctive treatment with risperidone in schizophrenic patients partially responsive to clozapine: efficacy and safety. J Clin Psychiatry 2005;66:63-72
   PubMed Web of Science ®Google Scholar
• Josiassen RC, Joseph A, Kohegyi E, et al. A clozapine augmented with risperidone in the treatment of schizophrenia: a randomized, double-blind, placebo-controlled trial. Am J Psychiatry 2005;162:130-6
   PubMed Web of Science ®Google Scholar
• Honer WG, Thornton AE, Chen EY, et al. Clozapine alone versus clozapine and risperidone with refractory schizophrenia. N Engl J Med 2006;354:472-82
   PubMed Web of Science ®Google Scholar
• Akdede BB, Anil Yağcioğlu AE, Alptekin K, et al. A double-blind study of combination of clozapine with risperidone in patients with schizophrenia: effects on cognition. J Clin Psychiatry 2006;67:1912-19
   PubMed Web of Science ®Google Scholar
• Freudenreich O, Henderson DC, Walsh JP, et al. Risperidone augmentation for schizophrenia partially responsive to clozapine: a double-blind, placebo-controlled trial. Schizophr Res 2007;92:90-4
   PubMed Web of Science ®Google Scholar
• Weiner E, Conley RR, Ball MP, et al. Adjunctive risperidone for partially responsive people with schizophrenia treated with clozapine. Neuropsychopharmacology 2010;35:2274-83
   PubMed Web of Science ®Google Scholar
• Kuwilsky A, Krumm B, Englisch S, et al. Long-term efficacy and tolerability of clozapine combined with ziprasidone or risperidone. Pharmacopsychiatry 2010;43:216-20
   PubMed Web of Science ®Google Scholar
• Chang JS, Ahn YM, Park HJ, et al. Aripiprazole augmentation in clozapine-treated patients with refractory schizophrenia: an 8-week, randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2008;69:720-31
   PubMed Web of Science ®Google Scholar
• Bachmann CJ, Lehr D, Theisen FM, et al. Aripiprazole as an adjunct to clozapine therapy in adolescents with early-onset schizophrenia: a retrospective chart review. Pharmacopsychiatry 2009;42:153-7
   Google Scholar
• Fleischacker WW, Heikkinen ME, Olie JP, et al. Effects of adjunctive treatment with aripiprazole on body weight and clinical efficacy in schizophrenia patients treated with clozapine: a randomized, double-blind, placebo-controlled trial. Int J Neuropsychopharmacol 2010;12:1115-25
   Google Scholar
• Benedetti A, Di Paolo A, Lastella M, et al. Augmentation of clozapine with aripiprazole in severe psychotic bipolar and schizoaffective disorders: a pilot study. Clin Pract Epidemiol Ment Health 2010;6:30-5
   PubMedGoogle Scholar
• Muscatello MR, Bruno A, Pandolfo G, et al. Effect of aripiprazole augmentation of clozapine in schizophrenia: a double-blind, placebo-controlled study. Schizophr Res 2011;127:93-9
   PubMed Web of Science ®Google Scholar
• Cipriani A, Accordini S, Nosè M, et al. Aripiprazole versus haloperidol in combination with clozapine for treatment-resistant schizophrenia: a 12-month, randomized, naturalistic trial. J Clin Psychopharmacol 2013;33:533-7
   PubMed Web of Science ®Google Scholar
• Shiloh R, Zemishlany Z, Aizenberg D, et al. Sulpiride augmentation in people with schizophrenia partially responsive to clozapine. A double-blind, placebo-controlled study. Br J Psychiatry 1997;171:569-73
   PubMed Web of Science ®Google Scholar
• Agelink MW, Kavuk I, Ak I. Clozapine with amisulpride for refractory schizophrenia. Am J Psychiatry 2004;161:924-5
   PubMed Web of Science ®Google Scholar
• Kampf P, Angelink MW, Naber D. Augmentation of clozapine with amisulpride: a promising therapeutic approach to refractory schizophrenic symptoms. Pharmacopsychiatry 2005;38:39-40
   PubMed Web of Science ®Google Scholar
• Munro J, Matthiasson P, Osborne S, et al. Amisulpride augmentation of clozapine: an open non-randomized study in patients with schizophrenia partially responsive to clozapine. Acta Psychiatr Scand 2004;10:292-8
   Google Scholar
• Genç Y, Taner E, Candansayar S. Comparison of clozapine-amisulpride and clozapine-quetiapine combinations for patients with schizophrenia who are partially responsive to clozapine: a single-blind randomized study. Adv Ther 2007;24:1-13
   PubMed Web of Science ®Google Scholar
• Assion HJ, Reinbold H, Lemanski S, et al. Amisulpride augmentation in patients with schizophrenia partially responsive or unresponsive to clozapine. A randomized, double-blind, placebo-controlled trial. Pharmacopsychiatry 2008;41:24-8
   PubMed Web of Science ®Google Scholar
• Hotham JE, Simpson PJ, Brooman-White RS, et al. Augmentation of clozapine with amisulpride: an effective therapeutic strategy for violent treatment-resistant schizophrenia patients in a UK high-security hospital. CNS Spectr 2013;28:1-8
   Google Scholar
• Zink M, Kuwilsky A, Krumm B, et al. Efficacy and tolerability of ziprasidone versus risperidone as augmentation in patients partially responsive to clozapine: a randomised controlled clinical trial. J Psychopharmacol 2009;23:305-14
   PubMed Web of Science ®Google Scholar
• Kuwilsky A, Krumm B, Englisch S, et al. Long-term efficacy and tolerability of clozapine combined with ziprasidone or risperidone. Pharmacopsychiatry 2010;43:216-20
   PubMed Web of Science ®Google Scholar
• Muscatello MR, Pandolfo G, Micò U, et al. Augmentation of clozapine with ziprasidone in refractory schizophrenia: a double-blind, placebo-controlled study. J Clin Psychopharmacol 2014;34:129-33
   PubMed Web of Science ®Google Scholar
• Friedman JI, Lindenmayer JP, Alcantara F, et al. Pimozide augmentation of clozapine inpatients with schizophrenia and schizoaffective disorder unresponsive to clozapine monotherapy. Neuropsychopharmacology 2011;36:1289-95
   PubMed Web of Science ®Google Scholar
• Gunduz-Bruce H, Oliver S, Gueorguieva R, et al. Efficacy of pimozide augmentation for clozapine partial responders with schizophrenia. Schizophr Res 2013;143:344-7
   PubMed Web of Science ®Google Scholar
• Nielsen J, Emborg C, Gydesen S, et al. Augmenting clozapine with sertindole: a double-blind, randomized, placebo-controlled study. J Clin Psychopharmacol 2012;32:173-8
   PubMed Web of Science ®Google Scholar
• Flynn SW, Altman S, MacEwan GW, et al. Prolongation of clozapine-induced granulocytopenia associated with olanzapine. J Clin Psychopharmacol 1997;17:494-5
   PubMed Web of Science ®Google Scholar
• Gupta S, Sonnenberg SJ, Frank B. Olanzapine augmentation of clozapine. Ann Clin Psychiatry 1998;10:113-15
   PubMedGoogle Scholar
• Buoli M, Dobrea C, Caldiroli A, et al. Augmentative asenapine in a recurrent manic catatonic patient with partial response to clozapine. Case Rep Psychiatry 2013;2013:503601
   PubMedGoogle Scholar
• Paraschakis A. Pipamperone augmentation of clozapine and sodium valproate in refractory schizophrenia: a case report. Clin Neuropharmacol 2014;37:60-1
   Google Scholar
• Hou YC. Improvement in psychotic symptoms and social functioning after augmentation of paliperidone with clozapine in a patient with schizoaffective disorder. J Neuropsychiatry Clin Neurosci 2014;26:E26
   Google Scholar
• Henderson DC, Fan X, Copeland PM, et al. Ziprasidone as an adjuvant for clozapine- or olanzapine-associated medical morbidity in chronic schizophrenia. Hum Psychopharmacol 2009;24:225-32
   PubMed Web of Science ®Google Scholar
• Muscatello MRA, Bruno A, Pandolfo G, et al. Topiramate augmentation of clozapine in schizophrenia: a double-blind, placebo-controlled study. J Psychopharmacol 2010;25:667-74
   Google Scholar
• Rummel-Kluge C, Komossa K, Schwarz S, et al. Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis. Schizophrenia Res 2010;123:225-33
   PubMed Web of Science ®Google Scholar
• Singh SP, Singh V, Kar N, Chan K. Efficacy of antidepressants in treating the negative symptoms of chronic schizophrenia: meta-analysis. Br J Psychiatry 2010;197:174-9
   PubMed Web of Science ®Google Scholar
• Buchanan RW, Kirkpatrick B, Bryant N, et al. Fluoxetine augmentation of clozapine treatment in patients with schizophrenia. Am J Psychiatry 1996;153:1625-7
   PubMed Web of Science ®Google Scholar
• Spina E, Avenoso A, Facciolà G, et al. Effect of fluoxetine on the plasma concentrations of clozapine and its major metabolites in patients with schizophrenia. Int Clin Psychopharmacol 1998;13:141-5
   PubMed Web of Science ®Google Scholar
• Anghelescu I, Szegedi A, Schlegel S, et al. Combination treatment with clozapine and paroxetine in schizophrenia: safety and tolerability data from a prospective open clinical trial. Eur Neuropsychopharmacol 1998;8:315-20
   Google Scholar
• Lu ML, Lane HY, Chen KP, et al. Fluvoxamine reduces the clozapine dosage needed in refractory schizophrenic patients. J Clin Psychiatry 2000;61:594-9
   PubMedGoogle Scholar
• Lu ML, Lane HY, Lin SK, et al. Adjunctive fluvoxamine inhibits clozapine-related weight gain and metabolic disturbances. J Clin Psychiatry 2004;65:766-71
   PubMed Web of Science ®Google Scholar
• Lan GX, Li ZC, Li L. A randomized, placebo-controlled clinical trial of combined citalopram and clozapine in the treatment of negative symptoms of schizophrenia. Chin Ment Health J 2006;20:696-8
   Google Scholar
• Zoccali R, Muscatello MR, Cedro C, et al. The effect of mirtazapine augmentation of clozapine in the treatment of negative symptoms of schizophrenia: a double-blind, placebo-controlled study. Int Clin Psychopharmacol 2004;19:71-6
   PubMed Web of Science ®Google Scholar
• Delle Chiaie R, Salviati M, Fiorentini S, Biondi M. Add-on mirtazapine enhances effects on cognition in schizophrenic patients under stabilized treatment with clozapine. Exp Clin Psychopharmacol 2007;15:563-8
   PubMed Web of Science ®Google Scholar
• Micò U, Bruno A, Pandolfo G, et al. Duloxetine as adjunctive treatment to clozapine in patients with schizophrenia: a randomized, placebo-controlled trial. Int Clin Psychopharmacol 2011;26:303-10
   PubMed Web of Science ®Google Scholar
• Santoro V, D’Arrigo C, Spina E, et al. Effect of adjunctive duloxetine on the plasma concentrations of clozapine, olanzapine, and risperidone in patients with psychotic disorders. J Clin Psychopharmacol 2010;30:634-6
   PubMed Web of Science ®Google Scholar
• Bruno A, Zoccali RA, Abenavoli E, et al. Augmentation of clozapine with agomelatine in partial-responder schizophrenia: a 16-week, open-label, uncontrolled pilot study. J Clin Psychopharmacol 2014;34:491-4
   Google Scholar
• Small JG, Klapper MH, Malloy FW, et al. Tolerability and efficacy of clozapine combined with lithium in schizophrenia and schizoaffective disorder. J Clin Psychopharmacol 2003;23:223-8
   PubMed Web of Science ®Google Scholar
• Bender S, Linka T, Wolstein J, et al. Safety and efficacy of combined clozapine-lithium pharmacotherapy. Int J Neuropsychopharmacol 2004;7:59-63
   Google Scholar
• Kelly DL, Conley RR, Feldman S, et al. Adjunct divalproex or lithium to clozapine in treatment-resistant schizophrenia. Psychiatr Q 2006;77:81-95
   PubMed Web of Science ®Google Scholar
• Dursun SM, Deakin JFW. Augmenting antipsychotic treatment with lamotrigine or topiramate in patients with treatment-resistant schizophrenia: a naturalistic case–series outcome studies. J Psychopharmacol 2001;15:297-301
   PubMed Web of Science ®Google Scholar
• Kremer I, Vass A, Gorelik I, et al. Placebo-controlled trial of lamotrigine added to conventional and atypical antipsychotics in schizophrenia. Biol Psychiatry 2004;56:441-6
   PubMed Web of Science ®Google Scholar
• Goff DC, Keefe R, Citrome L, et al. Lamotrigine as add-on therapy in schizophrenia: results of 2 placebo-controlled trials. J Clin Psychopharmacol 2007;27:582-9
   PubMed Web of Science ®Google Scholar
• Tiihonen J, Hallikainen T, Ryynanen OP, et al. Lamotrigine in treatment-resistant schizophrenia: a randomized placebo- controlled crossover trial. Biol Psychiatry 2003;54:1241-8
   PubMed Web of Science ®Google Scholar
• Zoccali R, Muscatello MR, Bruno A, et al. The effect of lamotrigine augmentation of clozapine in a sample of treatment-resistant schizophrenic patients: a double-blind, placebo-controlled study. Schizophr Res 2007;93:109-16
   PubMed Web of Science ®Google Scholar
• Vayısoğlu S, Anıl Yağcıoğlu AE, Yağcıoğlu S, et al. Lamotrigine augmentation in patients with schizophrenia who show partial response to clozapine treatment. Schizophr Res 2013;143:207-14
   PubMed Web of Science ®Google Scholar
• Spina E, D’Arrigo C, Migliardi G, et al. Effect of adjunctive lamotrigine treatment on the plasma concentrations of clozapine, risperidone and olanzapine in patients with schizophrenia or bipolar disorder. Ther Drug Monit 2006;28:599-602
   PubMed Web of Science ®Google Scholar
• Tiihonen J, Halonen P, Wahlbeck K. Topiramate add-on in treatment-resistant schizophrenia: a randomized, double-blind, placebo-controlled, crossover trial. J Clin Psychiatry 2005;66:1012-15
   PubMed Web of Science ®Google Scholar
• Afshar H, Roohafza H, Mousavi G, et al. Topiramate add-on treatment in schizophrenia: a randomised, double blind, placebo-controlled clinical trial. J Psychopharmacol 2008;23:157-62
   Google Scholar
• Behdani F, Hebrani P, Rezaei Ardani A, Rafee E. Effect of topiramate augmentation in chronic schizophrenia: a placebo-controlled trial. Arch Iran Med 2011;14:270-5
   PubMed Web of Science ®Google Scholar
• Hahn MK, Cohn T, Teo C, et al. Topiramate in schizophrenia: a review of effects on psychopathology and metabolic parameters. Clin Schizophr Relat Psychoses 2013;6:186-96
   PubMedGoogle Scholar
• Potkin SG, Jin Y, Bunney BG, et al. Effect of clozapine and adjunctive high-dose glycine in treatment-resistant schizophrenia. Am J Psychiatry 1999;156:145-7
   PubMedGoogle Scholar
• Diaz P, Bhaskara S, Dursun SM, Deakin B. Double-blind, placebo-controlled, crossover trial of clozapine plus glycine in refractory schizophrenia negative results. J Clin Psychopharmacol 2005;25:277-8
   Google Scholar
• Heresco-Levy U, Javitt DC, Ermilov M, et al. Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia. Arch Gen Psychiatry 1999;56:29-36
   PubMed Web of Science ®Google Scholar
• Evins AE, Fitzgerald SM, Wine L, et al. Placebo-controlled trial of glycine added to clozapine in schizophrenia. Am J Psychiatry 2000;157:826-8
   PubMed Web of Science ®Google Scholar
• Goff DC, Henderson DC, Evins AE, Amico E. A placebo-controlled crossover trial of D-cycloserine added to clozapine in patients with schizophrenia. Biol Psychiatry 1999;45:512-14
   PubMed Web of Science ®Google Scholar
• Goff DC, Tsai G, Manoach DS, et al. D-cycloserine added to clozapine for patients with schizophrenia. Am J Psychiatry 1996;153:1628-30
   PubMedGoogle Scholar
• Tsai GE, Yang P, Chung LC, et al. D-serine added to clozapine for the treatment of schizophrenia. Am J Psychiatry 1999;156:1822-5
   PubMed Web of Science ®Google Scholar
• Lane HY, Huang CL, Wu PL, et al. Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to clozapine for the treatment of schizophrenia. Biol Psychiatry 2006;60:645-9
   PubMed Web of Science ®Google Scholar
• Goff DC, Leahy L, Berman I, et al. A placebo-controlled pilot study of the ampakine CX516 added to clozapine in schizophrenia. J Clin Psychopharmacol 2001;21:484-7
   PubMed Web of Science ®Google Scholar
• de Lucena D, Fernandes BS, Berk M, et al. Improvement of negative and positive symptoms in treatment-refractory schizophrenia: a double-blind, randomized, placebo-controlled trial with memantine as add-on therapy to clozapine. J Clin Psychiatry 2009;70:1416-23
   PubMed Web of Science ®Google Scholar
• Stryjer R, Strous R, Bar F, et al. Donepezil augmentation of clozapine monotherapy in schizophrenia patients: a double blind cross-over study. Hum Psychopharmacol 2004;19:343-6
   PubMed Web of Science ®Google Scholar
• Fenton WS, Dickerson F, Boronow J, et al. A placebo-controlled trial of omega-3 fatty acid (ethyl eicosapentaenoic acid) supplementation for residual symptoms and cognitive impairment in schizophrenia. Am J Psychiatry 2001;158:2071-4
   PubMed Web of Science ®Google Scholar
• Peet M, Horrobin DF; E-E Multicentre Study Group. A dose-ranging exploratory study of the effects of ethyl-eicosapentaenoate in patients with persistent schizophrenic symptoms. J Psychiatr Res 2002;36:7-18
   PubMed Web of Science ®Google Scholar
• Emsley R, Myburgh C, Oosthuizen P, van Rensburg SJ. Randomized, placebo-controlled study of ethyl-eicosapentaenoic acid as supplemental treatment in schizophrenia. Am J Psychiatry 2002;159:1596-8
   PubMed Web of Science ®Google Scholar
• Remington G, Kapur S, Foussias G, et al. Tetrabenazine augmentation in treatment-resistant schizophrenia: a 12-week, double-blind, placebo-controlled trial. J Clin Psychopharmacol 2012;32:95-9
   PubMed Web of Science ®Google Scholar
• Levkovitz Y, Mendlovich S, Riwkes S, et al. A double-blind, randomized study of minocycline for the treatment of negative and cognitive symptoms in early-phase schizophrenia. J Clin Psychiatry 2010;71:138-49
   PubMed Web of Science ®Google Scholar
• Qurashi I, Collins J, Chaudhry I, Husain N. Promising use of minocycline augmentation with clozapine in treatment-resistant schizophrenia. J Psychopharmacol 2014;28:707-8
   Google Scholar
• Kho KH, Blansjaar BA, de Vries S, et al. Electroconvulsive therapy for the treatment of clozapine nonresponders suffering from schizophrenia - an open label study. Eur Arch Psychiatry Clin Neurosci 2004;254:372-9
   PubMed Web of Science ®Google Scholar
• Havaki-Kontaxaki BJ, Ferentinos PP, Kontaxakis VP, et al. Concurrent administration of clozapine and electroconvulsive therapy in clozapine-resistant schizophrenia. Clin Neuropharmacol 2006;29:52-6
   PubMed Web of Science ®Google Scholar
• Masoudzadeh A, Khalilian AR. Comparative study of clozapine, electroshock and the combination of ECT with clozapine in treatment-resistant schizophrenic patients. Pak J Biol Sci 2007;10:4287-90
   PubMedGoogle Scholar
• Kreyenbuhl J, Buchanan RW, Dickerson FB, Dixon LB. The schizophrenia patient outcomes research team (PORT): updated treatment recommendations 2009. Schizophr Bull 2010;36:94-103
   PubMed Web of Science ®Google Scholar
• Pai NB, Laidlaw M, Vella SC. Augmentation of clozapine with another pharmacological agent: treatment for refractory schizophrenia in the ’real world’. Acta Psychiatr Scand 2012;126:40-6
   Web of Science ®Google Scholar
• Remington G, Agid O, Foussias G, et al. Clozapine’s role in the treatment of first-episode schizophrenia. Am J Psychiatry 2013;170:146-51
   PubMed Web of Science ®Google Scholar
• Taylor DM, Smith L. Augmentation of clozapine with a second antipsychotic – a meta-analysis of randomized, placebo-controlled studies. Acta Psychiatr Scand 2009;119:419-25
   PubMed Web of Science ®Google Scholar
• Kontaxakis VP, Ferentinos PP, Havaki-Kontaxaki BJ, Roukas DK. Randomized controlled augmentation trials in clozapine-resistant schizophrenic patients: a critical review. Eur Psychiatry 2005;20:409-15
   PubMedGoogle Scholar
• Giegling I, Drago A, Schäfer M, et al. Interaction of haloperidol plasma level and antipsychotic effect in early phases of acute psychosis treatment. J Psychiatr Res 2010;44:487-92
   Google Scholar
• Hindmarch I, Hashimoto K. Cognition and depression: the effects of fluvoxamine, a sigma-1 receptor agonist, reconsidered. Hum Psychopharmacol 2010;25:193-200
   PubMed Web of Science ®Google Scholar
• Pollak TA, McCormack R, Peakman M, et al. Prevalence of anti-N-methyl-d-aspartate (NMDA) antibodies in patients with schizophrenia and related psychoses: a systematic review and meta-analysis. Psychol Med 2013;13:1-13
   Google Scholar
• Horrobin DF. The membrane phospholipid hypothesis as a biochemical basis for the neurodevelopmental concept of schizophrenia. Schizophr Res 1998;30:193-208
   PubMed Web of Science ®Google Scholar
• Molina JD, Jiménez-González AB, López-Muñoz F, Cañas F. Evolution of the concept of treatment-resistant schizophrenia: toward a reformulation for lack of an adequate response. J Exp Clin Med 2012;4:98-102
   Google Scholar
• Geyer MA, Olivier B, Joëls M, Kahn RS. From antipsychotic to anti-schizophrenia drugs: role of animal models. Trends Pharmacol Sci 2012;33:515-21
   PubMed Web of Science ®Google Scholar
• Harrison PJ, Weinberger DR. Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence. Mol Psychiatry 2005;10:40-68
   PubMed Web of Science ®Google Scholar